Anticoagulants: dose control methods and inhibitors
Obstetrics, Gynecology and Reproduction
; 16(2):158-175, 2022.
Article
in Russian
| EMBASE | ID: covidwho-1957618
ABSTRACT
These days, anticoagulants are in great demand. They are used as a prophylaxis for thromboembolic complications in various diseases and conditions in general therapeutic practice, cardiology, neurology, as well as obstetrics to manage high-risk pregnancies. The relevance of anticoagulants competent use has come to the fore in connection with the emergence of a new disease – COVID-19 and its serious complications such as developing thrombotic storm, in which the timely applied anticoagulant therapy is the key to the success of therapy. The risk of bleeding should be considered when using any anticoagulant. Age, impaired renal function and concomitant use of antiplatelet agents are common risk factors for bleeding. Moreover, only vitamin K antagonists and heparin have specific antidotes – vitamin K and protamine, respectively. Inhibitors of other anticoagulants are universal presented as inactivated or activated prothrombin complex concentrate and recombinant factor VIIa. Hemodialysis effectively reduces dabigatran concentration, activated charcoal is effective in the case of recent oral administration of lipophilic drugs. Research on new antidotes of currently available anticoagulants is under way, similar to testing of new types of anticoagulants that are sufficiently effective in preventing and treating thromboembolic complications with minimal risk of hemorrhagic. The main contraindication to anticoagulants use is the doctor's ignorance of the mechanisms of drug action and opportunities for suppressing its effect.
anticoagulant therapy; article; bleeding; cardiology; complication; contraindication; controlled study; coronavirus disease 2019; drug mechanism; drug therapy; hemodialysis; high risk pregnancy; human; human cell; kidney failure; lipophilicity; neurology; obstetrics; oral drug administration; prophylaxis; risk factor; thromboembolism; thrombotic storm; activated carbon; activated prothrombin complex; anticoagulant agent; antidote; antithrombocytic agent; antivitamin K; blood clotting factor 10a inhibitor; dabigatran; endogenous compound; heparin; low molecular weight heparin; protamine; recombinant blood clotting factor 7a; thrombin inhibitor; vitamin K group; warfarin
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
Russian
Journal:
Obstetrics, Gynecology and Reproduction
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS